LPC omega-3 (Lysophosphatidylcholine) represents a revolutionary advancement in omega-3 supplementation. Unlike conventional fish oil that contains omega-3s in triglyceride form, LPC-bound omega-3s can cross the blood-brain barrier to deliver DHA and EPA directly to your brain.
What Does LPC Stand For?
LPC stands for Lysophosphatidylcholine – a specific molecular form of phospholipid that your brain recognizes and actively transports across the blood-brain barrier via the MFSD2A receptor. This is the natural form your brain uses to build and maintain neuronal membranes.
What is Lysoveta LPC?
Lysoveta® is the patented LPC omega-3 technology developed by Aker BioMarine, a leading Norwegian biotechnology company specializing in krill-based omega-3s. It is a food-based advanced omega-3 form made from concentrated Krill oil. Lysoveta is the clinically-studied form of LPC-bound EPA and DHA used in OmegaBrite’s premier LPC Brain Elite Lyso-DHA supplement. The brain is a fortress that protects itself with the Blood Brain Barrier that prevents regular triglyceride, ethyl ester or phospholipid forms of omega-3 from getting into the brain. It has a locked door and only one type of omega-3 is the key–LPC DHA and LPC EPA. Lysoveta is a mixture of LPC rich omega-3 that provides the brain with this exact LPC form of Omega-3 that fits the MFSD2A transporter for immediate absorption into the brain. OmegaBrite LPC Brain Elite uses this advanced VIP delivery provides your brain with the Lyso-DHA omega-3 it needs.
Reference: Aker BioMarine. “Lysoveta: The next generation of omega-3 for brain health.” https://www.lysoveta.com/science
How is LPC Omega-3 Different from Fish Oil?
| Feature | Standard Fish Oil | LPC Omega-3 (Lysoveta) |
|---|---|---|
| Form | Triglyceride-bound | Lysophosphatidylcholine-bound |
| Blood-Brain Barrier | Cannot cross efficiently | Actively transported via MFSD2A |
| Brain Absorption | Less than 0.1% | Up to 6x higher |
| Primary Benefit | Heart health | Brain & cognitive health |
Reference: Chen, C. T., et al. (2015). “Plasma non-esterified docosahexaenoic acid is the major source of brain docosahexaenoic acid in the rat.” Journal of Lipid Research, 56(5), 941-955.
The Science: MFSD2A Transporter
In 2014, researchers discovered the MFSD2A transporter – a protein on the blood-brain barrier that specifically recognizes and transports LPC-bound fatty acids into brain tissue. This discovery, published in Nature, explained why traditional fish oil has poor brain bioavailability.
Reference: Nguyen, L. N., et al. (2014). “Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid.” Nature, 509(7501), 503-506. https://www.nature.com/articles/nature13241
Benefits of LPC Omega-3
- Enhanced Brain Delivery: Up to 6x better absorption than standard fish oil
- Cognitive Support: Supports memory, focus, and mental clarity
- Neuroprotection: Helps protect brain cells from age-related decline
- Eye Health: Delivers targeted nourishment to the retina
Reference: Yalagala, P. C., et al. (2018). “Dietary lysophosphatidylcholine-EPA enriches both EPA and DHA in the brain of aged rats.” PMC, 6399499. https://pmc.ncbi.nlm.nih.gov/articles/PMC6399499/
Who Should Take LPC Omega-3?
LPC omega-3 is ideal for:
- Adults concerned about cognitive health
- People who haven’t seen results from regular fish oil
- Those seeking enhanced focus and mental clarity
- Older adults experiencing age-related cognitive changes
- APOE4 gene carriers (higher Alzheimer’s risk)
Reference: Andriambe, B., et al. (2025). “Providing lysophosphatidylcholine-bound omega-3 fatty acids to mice: Effects on brain fatty acid concentrations.” PubMed. https://pubmed.ncbi.nlm.nih.gov/39509986/
OmegaBrite’s Approach: The Complete Omega-3 System
At OmegaBrite, we believe in offering the most effective omega-3 solutions for your specific needs:
- OmegaBrite 7010MD: Our flagship high-EPA formula (70% EPA / 10% DHA) – doctor-formulated by Dr. Carol Locke and backed by published clinical studies showing 20% anxiety reduction
- OmegaBrite LPC Brain Elite: Powered by Lysoveta technology from Aker BioMarine for superior brain delivery via the MFSD2A transporter
Used together, these products provide comprehensive omega-3 support for both body and brain.
Clinical Evidence for OmegaBrite 7010MD
While LPC omega-3s are newer to the market, our OmegaBrite 7010MD has been studied in published clinical trials:
Ohio State University Study (2011)
- Participants: 68 medical students
- Duration: 12 weeks
- Results: 20% reduction in anxiety, 14% reduction in inflammatory markers
- Published: Brain, Behavior, and Immunity
Reference: Kiecolt-Glaser, J. K., et al. (2011). “Omega-3 supplementation lowers inflammation and anxiety in medical students: A randomized controlled trial.” Brain, Behavior, and Immunity, 25(8), 1725-1734. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191260/
Conclusion
The discovery of the MFSD2A transporter has fundamentally changed our understanding of brain nutrition. Form matters more than dose: a lower amount of LPC-bound omega-3 can deliver significantly more DHA to your brain than a much higher dose of fish oil.
If brain health is your priority, choosing omega-3s in the form your brain can actually absorb isn’t just smart—it’s essential.
Ready to experience the next generation of omega-3? Shop OmegaBrite LPC Brain Elite or learn more about our clinically-studied 7010MD formula.
References and Further Reading
- Nguyen, L. N., et al. (2014). “Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid.” Nature, 509(7501), 503-506.
- Yalagala, P. C., et al. (2018). “Dietary lysophosphatidylcholine-EPA enriches both EPA and DHA in the brain of aged rats.” PMC, 6399499.
- Chen, C. T., et al. (2015). “Plasma non-esterified docosahexaenoic acid is the major source of brain docosahexaenoic acid in the rat.” Journal of Lipid Research, 56(5), 941-955.
- Andriambe, B., et al. (2025). “Providing lysophosphatidylcholine-bound omega-3 fatty acids to mice.” PubMed.
- Kiecolt-Glaser, J. K., et al. (2011). “Omega-3 supplementation lowers inflammation and anxiety in medical students.” Brain, Behavior, and Immunity, 25(8), 1725-1734.
- Aker BioMarine. “Lysoveta Clinical Studies.” https://www.lysoveta.com/science
